Nom du produit:(1S,3S,4R)-Ethyl2-((R)-1-phenylethyl)-2-azabicyclo[2.2.2]oct-5-ene-3-carboxylate

IUPAC Name:ethyl (1S,3S,4R)-2-[(1R)-1-phenylethyl]-2-azabicyclo[2.2.2]oct-5-ene-3-carboxylate

CAS:134984-64-8
Formule moléculaire:C18H23NO2
Pureté:97%
Numéro de catalogue:CM494928
Poids moléculaire:285.39

Unité d'emballage Stock disponible Prix($) Quantité
CM494928-1g 1-2 Weeks ưȎź

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:134984-64-8
Formule moléculaire:C18H23NO2
Point de fusion:-
Code SMILES:O=C([C@H]1N([C@@H](C2=CC=CC=C2)C)[C@]3([H])C=C[C@@]1([H])CC3)OCC
Densité:
Numéro de catalogue:CM494928
Poids moléculaire:285.39
Point d'ébullition:
N° Mdl:MFCD27978833
Stockage:

Column Infos

DSP-5336
Sumitomo Pharma announces that DSP-5336 has received FDA Fast Track Designation for the treatment of relapsed or refractory acute myeloid leukemia (AML) with a KMT2A rearrangement, also known as, mixed lineage leukemia rearrangement (MLLr) or nucleophosmin mutation (NPM1m). Menin serves as a tumor suppressor in endocrine glands. Novel menin inhibitors are novel targeted agents in clinical studies targeting genetically defined subsets of acute leukemia.
DSP-5336 is an investigational menin-MLL interaction inhibitor. DSP-5336 has been granted Orphan Drug Designation in acute myeloid leukemia, and Fast Track Designation in relapsed or refractory acute myeloid leukemia with MLLr or NPM1m.

Related Products